• search
Application of mPEGs in Drug Discovery and Development Application of mPEGs in Drug Discovery and Development

Application of mPEGs in Drug Discovery and Development

PUBLISHED ON:
January 4, 2021
CATEGORY:
Development and Manufacturing
Application of mPEGs in Drug Discovery and Development

Methoxy Polyethylene Glycols (mPEGs) are increasingly being applied in drug discovery and drug development to enhance the deliverability and bioavailability of the drug, and to increase the serum half-life. Today, due to advancements in chemical processes and purification techniques it is possible to produce high-quality mPEGs.

mPEGs in combination with a small molecule drug can negate the disadvantages of poor solubility, inefficient action on the target site, low presence in the bloodstream, and toxicity. When combined with a large molecule, they help increase the half-life, resident time in the blood and help prevent the immune system responses of the body from detecting the drug as an antibody.

Methoxypolyethylene Glycols (mPEGs) have a range of applications in drug discovery and development

  • Dermatology Drugs – m-PEGs being hydrophobic easily penetrate the skin on application, especially in the form of a topical formulation. Their low toxicity also makes them suitable for dermatological applications.
  • Highly Potent Oncology Drugs – Methoxy PEGs are used to deliver drugs in chemotherapy to increase their effectiveness. Methoxy Polyethylene nanoparticles can be loaded with the required drug to increase its stability in the body and reduce overall toxicity.
  • Polypeptide Drugs – As polypeptide drugs are unstable and degrade quickly thus reducing the half-life and amount of exposure in the bloodstream. When a polypeptide drug is combined with an m-PEG, both half-life and stability increase.
  • Large Molecule Drugs – Large molecule drugs degrade quickly and get cleared from the bloodstream in a short period of time. If they are bound with mPEGs they maintain their desired form, have a greater half-life, and are not recognized as anti-bodies by the immune system.

Social Share

Latest Posts

Transforming Drug Discovery with Aurigene.AI

Transforming Drug Discovery with Aurigene.AI

March 12, 2025
Arrow sign
ADMET Predictive Models in Aurigene.AI

ADMET Predictive Models in Aurigene.AI

January 30, 2025
Arrow sign
Protac Research

PROTACs: Research for a life without cancer

October 9, 2024
Arrow sign
Toxicology assessment to accelerate IND and NDA Submissions

Good practices in non-clinical toxicology assessment to accelerate IND and NDA Submissions

October 9, 2024
Arrow sign
Continuous Flow Chemistry

Continuous Flow Chemistry: A Game-Changer for Pharmaceutical Production

September 17, 2024
Arrow sign
Why meet us at CPHI Milan?

Why meet us at CPHI Milan?

August 29, 2024
Arrow sign
CDMO white paper

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Immuno oncology cdmo

Immuno Oncology - Therapies and Challenges

long term partnership with cdmo

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack